

Special Issue

Antibiotic Resistance and Treatment of MRSA Infection

Message from the Guest Editor

Staphylococcus aureus is a major human pathogen associated with hospital-acquired infections, as well as an emerging cause of community-acquired infections. The selective pressure exerted by the appropriate and/or inappropriate use of antibiotics to treat *S. aureus* infections results in diverse resistance genes that lead to the development of antimicrobial resistance. Moreover, *S. aureus* capacity to form biofilms, to antimicrobial resistance and makes treatment more challenging. This Issue thus aims to provide various strategies to treat MRSA infections. Moreover, studies aiming at elucidating the molecular basis of antimicrobial resistance, target identification, and drug development are also welcome. The overall aim is to bring together the most up-to-date perspectives and research in the areas of:

- Development of novel drugs, vaccines, and preventive strategies against MRSA infection;
- Adjuvant to antibiotics/combination therapy;
- Molecular determinant of antimicrobial resistance;
- Successes and challenges for MRSA infection control.

Keywords: MRSA; antimicrobial resistance; *mecA*; PBP; lactamase; biofilm formation; drug discovery

Guest Editor

Dr. Jae-Seok Kim

Department of Laboratory Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea

Deadline for manuscript submissions

closed (15 March 2021)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/45448

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)